Actively Recruiting
Fruquintinib in Patients With Metastatic Colorectal Cancer
Led by iOMEDICO AG · Updated on 2026-04-06
150
Participants Needed
1
Research Sites
145 weeks
Total Duration
On this page
Sponsors
I
iOMEDICO AG
Lead Sponsor
T
Takeda GmbH
Collaborating Sponsor
AI-Summary
What this Trial Is About
FRUQUENT is an observational study in Germany. The goal of the study is to evaluate how well Fruquintinib works to treat patients with metastatic colorectal cancer that have previously been treated with available standard therapies. To this end, it will be analyzed how well patients respond to the therapy in the clinical routine. Further points of interest to the study are survival data, safety data, the use of medical care facilities, and the quality of life of patients treated with Fruquintinib. Participants will be treated as decided by the treating physician and according to their routine practice. FRUQUENT is accompanied by a translational research project combining real-world clinical data with foundational research to stratify patient collectives in regards to the therapeutic benefit of fruquintinib.
CONDITIONS
Official Title
Fruquintinib in Patients With Metastatic Colorectal Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aged 18 years or older.
- Indication and decision for therapy with fruquintinib in accordance with the current German SmPC as monotherapy for metastatic colorectal cancer.
- Prior treatment with standard therapies including fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapies, anti-VEGF therapy, and if RAS wild-type, anti-EGFR therapy.
- Progression on or intolerance to treatment with trifluridine/tipiracil and/or regorafenib.
- Other criteria according to current SmPC.
- Signed written informed consent.
- Patients may be enrolled up to 6 weeks after first fruquintinib dose but cannot participate in PRO assessments if enrolled late.
You will not qualify if you...
- Participation in an interventional clinical trial (except follow-up) within 30 days prior to enrollment or start of fruquintinib treatment.
- Contraindications as per current SmPC.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Onkologische Schwerpunktpraxis
Hanover, Lower Saxony, Germany, 30161
Actively Recruiting
Research Team
M
Max D Mai, MSc
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here